We evaluated the safety and efficacy of the hepatitis C virus (HCV) NS3/4A A protease inhibitor faldaprevir plus pegylated interferon α-2b and ribavirin (PegIFNα-2b/RBV) in Japanese patients with HCV genotype-1 infection.
INTRODUCTION

I
N JAPAN, APPROXIMATELY 2 million people are chronically infected with hepatitis C virus (HCV), predominantly genotype (GT)-1 subtype b. The current recommended treatment for chronic HCV GT-1 infection in Japan is triple therapy with the non-structural (NS) 3/4A protease inhibitor simeprevir plus pegylated interferon plus ribavirin (PegIFN/RBV). 1 Simeprevir is better tolerated than earlier protease inhibitors, with sustained virologic response (SVR) rates of approximately 90% achieved in clinical studies in treatment-naïve Japanese patients with GT-1 infection. 2, 3 In treatment-experienced patients, the reported response rate varied according to previous response to IFN-based treatment: while high response rates (up to 97%) were achieved in prior relapsers, patients who had failed to respond to previous IFN-based therapy had a poor response to simeprevirbased triple therapy (≤53%). 3, 4 Thus, there is still a need for improved treatment options for these patients.
Faldaprevir, a potent HCV NS3/4A A protease inhibitor with a pharmacokinetic profile that supports once-daily (q.d.) dosing, 5, 6 has been evaluated in phase II and III trials for HCV GT-1 infection in treatment-naïve and treatmentexperienced patients in combination with PegIFN/RBV. [7] [8] [9] [10] [11] [12] [13] In treatment-naïve patients, SVR rates of 72-84% were achieved with faldaprevir 120 mg q.d. plus PegIFN/RBV. 7, 10 In treatment-experienced patients, faldaprevir 240 mg q.d. plus PegIFN/RBV resulted in SVR rates of 50-53% and 33-35% in patients with prior partial and prior null response, respectively. 8, 12, 13 Patients with prior relapse achieved SVR rates of approximately 70%. 12 All previous clinical studies of faldaprevir plus PegIFN/RBV were undertaken using PegIFNα-2a. The objectives of this phase III study were to assess the safety and efficacy of faldaprevir, dosed at 120 or 240 mg q.d. for 12 or 24 weeks, in combination with PegIFNα-2b/RBV, for 24 or 48 weeks, in treatment-naïve and treatment-experienced Japanese patients with chronic GT-1 HCV infection. Since the completion of this analysis, the development of faldaprevir has been terminated. However, the study provides valuable information about HCV NS3 protease inhibitor therapy in treatmentnaïve and treatment-experienced Japanese patients that may be relevant to the use of other direct-acting antivirals.
METHODS
Study design and patients
T HIS WAS A phase III multicenter trial carried out at 24 sites in Japan between April 2012 and December 2013. The trial consisted of two parts. The first part (Cohort 1) was a randomized, double-blind, parallel-group study in treatment-naïve patients. The second part (Cohort 2) was an open-label study in treatment-experienced patients. Eligible patients were aged 20-70 years with a diagnosis of chronic HCV GT-1 infection, determined by positive anti-HCV antibodies and HCV RNA ≥100 000 IU/mL at screening in addition to either a liver biopsy consistent with chronic HCV infection or positive anti-HCV antibodies or detectable HCV RNA at least 6 months before screening. Patients were required to have undergone a liver biopsy within 3 years or liver elastography within 6 months of randomization. The HCV subtype of screening plasma samples was determined using the VERSANT HCV Genotype 2.0 (LiPA) assay (Siemens, Erlangen, Germany). For patients without a liver biopsy, fibrosis stage was determined by FibroScan (Echosens, Paris, France; F0-F2, <9.5 kPa; F3-F4, ≥9.5 kPa). If neither assessment was carried out and the patient was indicated to have cirrhosis, then a METAVIR score of ≥F3 was recorded. In Cohort 1, patients were naïve to IFN, PegIFN/RBV, or any antiviral/ immunomodulatory drug for acute or chronic HCV infection. Patients in Cohort 2 had confirmed prior virologic failure (relapse, breakthrough, partial response, or null response) with an approved dose of PegIFNα/RBV or IFNβ/RBV for at least 12 weeks and with an 8-week washout period before screening. Prior virologic failure was categorized as follows: relapse, HCV RNA undetectable (based on an assay considered sensitive at the time of treatment) at the end of the treatment course but detectable within 24 weeks of follow-up; breakthrough, HCV RNA undetectable during treatment but confirmed HCV RNA rebound to detectable levels during ongoing treatment; partial response, HCV RNA drop by ≥2 log 10 from baseline at week 12 ± 2 weeks, but never HCV RNA <25 IU/mL undetectable on treatment; or null response, absence of HCV RNA drop by ≥2 log 10 from baseline at week 12 ± 2 weeks. Key exclusion criteria were: mixed genotype HCV, evidence of non-HCV-related liver disease, hepatitis B infection, HIV infection, decompensated liver disease, clinically significant comorbidities, hemoglobin <12 g/dL (women) or <13 g/dL (men), and hypersensitivity to the study treatments.
Study documentation was approved by the appropriate institutional review board. The study was carried out in accordance with the Declaration of Helsinki, Japanese Good Clinical Practice regulations, and International Conference on Harmonisation guidelines. Informed consent was obtained from all patients included in the study. An independent project data monitoring committee reviewed data at least every 4 months to ensure that the welfare of patients participating in the trial was maintained.
Treatments
Using an interactive Web response system, patients in Cohort 1 were randomized 1:1 to receive faldaprevir 120 mg q.d. for 12 or 24 weeks in combination with PegIFNα-2b/RBV or faldaprevir 240 mg q.d. for 12 weeks in combination with PegIFNα-2b/RBV (Fig. 1a) . Duration of PegIFNα-2b/RBV was determined by response-guided therapy (RGT): patients who achieved early treatment success (ETS; HCV RNA <25 IU/mL detected or undetected at week 4 and <25 IU/mL undetected at week 8) stopped all treatment at week 24; those without ETS received extended treatment with PegIFNα-2b/RBV up to week 48. Duration of faldaprevir 120 mg q.d. was also based on RGT; patients with ETS received 12 weeks of faldaprevir and those without received 24 weeks of faldaprevir. Randomization was stratified by IL28B polymorphism (CC/non-CC at rs12979860) and presence of compensated liver cirrhosis (yes/no).
In Cohort 2, treatment-experienced patients were assigned to one of two treatment groups depending on previous treatment response (Fig. 1b) . Relapsers received Faldaprevir in Japanese HCV patients E143 Hepatology Research 2017; 47: E142-E151 faldaprevir 240 mg q.d. combined with PegIFNα-2b/RBV for 24 weeks, while non-relapsers (partial responders, breakthrough, and null responders) received faldaprevir 240 mg q.d. combined with PegIFNα-2b/RBV for 24 weeks followed by an additional 24 weeks of PegIFNα-2b/RBV. All relapsers who achieved ETS stopped all treatment at week 24, whereas those who did not achieve ETS received extended treatment with PegIFNα-2b/RBV up to week 48.
All patients received a double dose of faldaprevir on day 1 as a lead-in dose. Pegylated IFNα-2b was given subcutaneously once weekly according to local prescribing information (PegIntron®; MSD K.K., Tokyo, Japan). Ribavirin was given orally twice daily according to local prescribing information (Rebetol®; MSD K.K.). Study treatments were administered with food (a requirement of RBV). Dose reductions or temporary discontinuation was permitted for PegIFNα-2b/RBV. If PegIFNα-2b was discontinued, RBV and faldaprevir had to be discontinued within 7 days. If only faldaprevir was discontinued, patients could continue on PegIFNα-2b/RBV if medically appropriate. Faldaprevir monotherapy was not permitted.
The use of growth factors, for example, granulocyte-colony stimulating factor or erythropoiesis-stimulating agents were prohibited because these drugs had not yet been approved for the treatment of patients with HCV infection in Japan at the time of the study. Concomitant treatment with medications that were cytochrome P450 3A (CYP3A) or uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1) substrates with a narrow therapeutic range was discouraged because of the potential of drug-drug interactions with faldaprevir.
Plasma HCV RNA levels were measured at screening, baseline, weeks 1, 2, 4, 8, 12, 18, 24, and at end of treatment, using the quantitative Roche COBAS TaqMan HCV 2.0 (Pleasanton, CA, USA), with a lower limit of detection of between 10 and 20 IU/mL and a lower limit of quantification of 25 IU/mL. Hepatitis C virus RNA levels are reported as <25 IU/mL undetected or <25 IU/mL detected. All study medication was stopped in the event of virologic failure. In Cohort 1, virologic failure was defined as: an increase of HCV RNA ≥1 log 10 from nadir or HCV RNA ≥25 IU/mL detected following an initial decrease to <25 IU/mL in two consecutive measurements within 2 weeks apart after week 4; lack of early virologic response (reduction in HCV RNA ≥2 log 10 from baseline at week 12); or lack of virologic response (HCV RNA detected at week 24). In Cohort 2, virologic failure was defined as: lack of HCV RNA reduction of ≥2 log 10 from baseline at week 4; HCV RNA reduction of ≥2 log 10 from baseline at week 4 but detectable at week 12; or increase of HCV RNA ≥1 log 10 from nadir or HCV RNA ≥25 IU/mL after an initial decrease to <25 IU/mL in two consecutive measurements within 2 weeks apart after week 4. All patients were to be followed up for 24 weeks after the end of study treatment.
End-points
The primary objective of the study was safety. Safety end-points included overall all-cause adverse events (AEs), drug-related AEs (investigator defined), vital signs, physical examination and 12-lead ECG, AEs leading to treatment discontinuation, serious AEs, and laboratory abnormalities. Intensity of AEs was classified by Division of Acquired Immunodeficiency Syndrome (DAIDS; version 1.0; http://www.niaid.nih.gov/labsandresources/resources /daidsclinrsrch/documents/daidsaegradingtable.pdf)
No primary efficacy end-point was defined. Secondary efficacy end-points were SVR (HCV RNA <25 IU/mL undetected) 12 weeks and 24 weeks after treatment discontinuation, ETS (defined earlier), and alanine aminotransferase and aspartate aminotransferase normalization. 
Resistance testing
Population-based sequencing of the HCV NS3/4A A protease and HCV core regions was performed by Janssen Diagnostics (Beerse, Belgium) for plasma samples from all patients at baseline and for post-baseline samples from patients who did not achieve SVR. Viral RNA was extracted and cDNA was synthesized using genotype-specific primers. Nucleotide sequences of the HCV core region (spanning codons , the full length NS3/4A A (codons 1-685), or the NS3 protease domain (codons 1-181) were obtained by direct DNA sequencing of the amplified product. Population-based sequencing allowed for the detection of variants present at approximately ≥30%. Hepatitis C virus subtype was re-assessed based on phylogenetic analyses of baseline NS3/4A A nucleotide sequences with subtype-specific references.
Statistical analysis
The planned sample size was 120 patients with 40 treatment-naïve patients per dose group and 40 treatmentexperienced patients. Sample size was not based on power calculation; all analyses were descriptive in nature and no hypothesis was tested. Analysis of safety was carried out on an as-treated basis. Adverse events were coded by using the Medical Dictionary for Regulatory Activities (http:// www.meddra.org/). Efficacy analyses were carried out for all patients who were assigned to a treatment and received at least one dose of study medication. Patients with missing SVR data (e.g. due to withdrawal or loss to follow-up) were considered treatment failures. Missing SVR12 data were imputed by the SVR24 result of the same patient where available.
RESULTS
Patients
I N COHORT 1, 103 patients were enrolled and 87 were randomized and treated; 44 in the faldaprevir 120 mg group and 43 in the faldaprevir 240 mg group (Fig. S1a) . Among patients in the 120 mg RGT group, 3/44 (6.8%) discontinued faldaprevir (one for an AE, one for lack of efficacy, and one withdrawal) and 2/44 (4.5%) discontinued PegIFNα-2b/RBV (one for lack of efficacy and one withdrawal). Among patients in the faldaprevir 240 mg 12 week group, 13/43 (30.2%) discontinued faldaprevir (all for AEs) and 12/43 (27.9%) discontinued PegIFNα-2b/RBV (nine for AEs, two for protocol violations, and one for lack of efficacy). In Cohort 2, 51 patients were enrolled and 44 were randomized and treated, including 29 prior relapsers and 15 prior non-relapsers (three patients with partial response, 10 with null response, and two patients with breakthrough) (Fig. S1b) . Of the 29 patients in the prior relapser group, two (6.9%) discontinued faldaprevir for AEs and one discontinued PegIFNα-2b/ RBV for AEs. Among prior non-relapsers, two (13.3%) discontinued faldaprevir (one for AEs and one for lack of efficacy) and six (40%) discontinued PegIFNα-2b/RBV (two for AE and four for lack of efficacy). Patient demographics and baseline disease characteristics were generally similar across cohorts and across treatment groups (Table 1 ). All patients were of Asian race. All treatmentnaïve patients, and all but one treatment-experienced patient, were infected with HCV GT-1b; one null responder was infected with HCV GT-1a. In Cohort 1, 25.6% (11/43) of patients in the faldaprevir 240 mg group had a fibrosis score of ≥F3 (or equivalent) and 2.3% (1 patient) had cirrhosis, compared with 11.4% (5/44) and 4.5% (2 patients), respectively, in the faldaprevir 120 mg group. In Table 2 Key safety end-points of phase III trial of faldaprevir (FDV) in combination with pegylated interferon α-2b and ribavirin (P/R) in treatment-naïve and treatment-experienced Japanese patients with genotype-1 chronic hepatitis C virus infection 
Safety and tolerability
Across the two cohorts, all 131 patients experienced at least one AE and 130 experienced at least one AE that was considered by the investigator to be drug related (Table 2) . Across treatment groups, the most frequently reported drug-related AEs were pyrexia, nausea, and rash. Nausea and diarrhea were more frequently reported with faldaprevir 240 mg than with faldaprevir 120 mg. Serious AEs were uncommon (8/131 [6%]) and there were no deaths. DAIDS grade 4 AEs were reported in two patients: one in the faldaprevir 120 mg group (neutropenia) and one in the faldaprevir 240 mg 24 week group (increased blood bilirubin). In the faldaprevir 120 mg group, most AEs were mild and there was only one treatment discontinuation (of faldaprevir only) due to an AE of nausea. In the faldaprevir 240 mg 12 week group, 31/43 (72%) patients experienced AEs of DAIDS grade ≥2 and 13 patients discontinued faldaprevir (±PegIFNα-2b/RBV) treatment for AEs (including rash and nausea each for three patients; erythema multiforme and vomiting each for two patients; vertigo, thyroiditis, retinal hemorrhage, fatigue, jaundice, decreased appetite, dehydration, altered state of consciousness, and hyperventilation each for one patient). In the faldaprevir 240 mg 24 week group, AEs of DAIDS grade ≥2 were reported for 22/44 (50%) patients and three Faldaprevir in Japanese HCV patients E147 Hepatology Research 2017; 47: E142-E151 patients experienced AEs leading to discontinuation of faldaprevir: nausea and vomiting each for two patients and thrombocytopenia for one patient. Rash events (special search category) were reported in approximately 55% of patients overall (Table 2) . Most rash events were mild or moderate with five patients reporting DAIDS grade 3 rash events and none with DAIDS grade 4 rash events. Hemoglobin ≤10 g/dL was observed in 29-36% of patients; hemoglobin ≤8.5 g/dL was infrequent (Table 2 ). Most anemia events were managed with RBV dose reduction.
Efficacy end-points
Efficacy end-points for both cohorts are summarized in Figure 2 and Table 3 . In Cohort 1 (treatment-naïve) rates of SVR12 and SVR24 were numerically higher in the faldaprevir 120 mg RGT group than in the faldaprevir 240 mg group. In the faldaprevir 120 mg group, almost all patients (97.7%) achieved ETS and received 12 weeks of treatment with faldaprevir and 24 weeks of treatment with PegIFNα-2b/RBV; the majority of these patients (88.4%) achieved SVR12. Among the 6/44 patients (13.6%) who did not achieve SVR12 in this group, 2/6 had virologic breakthrough and 4/6 experienced posttreatment relapse. In the faldaprevir 240 mg 12 week group, 93.0% of patients achieved ETS and received 24 weeks of treatment with PegIFNα-2b/RBV; 80% of these patients achieved SVR12. Of the 11/43 (25.6%) patients who did not achieve SVR12 in this group, 2/11 had virologic breakthrough, 5/11 had relapse, and 4/11 discontinued treatment.
In Cohort 2, 28/29 (96.9%) prior relapsers achieved ETS and discontinued all treatment at week 24; 25 (89.3%) of these achieved SVR12. In this group, four patients (13.8%) failed to achieve SVR12 (3/4 patients relapsed and 1/4 discontinued). Among prior non-relapsers, 11/15 (73.3%) achieved ETS and seven (63.6%) of these achieved SVR12. Among prior partial responders/breakthroughs, two (40%) did not achieve SVR12 (one had breakthrough and for one the reason was given as "other"). In the prior null responder group, six (60%) did not achieve SVR12 (2/6 had breakthrough, 3/6 had relapse, and 1/6 discontinued). Table 4 shows SVR12 rates by subgroup for Cohorts 1 and 2. The SVR12 rate was higher in patients with an IL28B genotype CC (rs12979860) than in those with a CT genotype in both cohorts. In Cohort 2, patients with a baseline viral load of <800 000 IU/mL and patients with non-elevated baseline GGT had higher SVR12 rates than patients in the complementary subgroups. No major differences were observed for other subgroups.
Resistance
Hepatitis C virus NS3 protease population-based sequences were available from 131 individual baseline Table 4 No single NS3 protease amino acid polymorphism was associated with a large reduction in SVR12. The difference in SVR12 among GT-1b-infected patients with baseline virus encoding arginine (R) at core amino acid 70 (82.4%, 70/85) and the SVR12 among patients with any other amino acid at core 70 (71.1%, 32 of 45 patients including 35 with Q, 6 with H or H/Q, 2 with Q/R, and 2 without sequence available) was not statistically significant (P = 0.1786).
The NS3 D168V amino acid substitutions were the predominant treatment-emergent resistance-associated variants (RAVs) detected in 73% (19/26) of GT-1b-infected patients who did not achieve SVR12, and D168E/I/N/T were detected to a lesser extent (19%, 5/26). NS3 R155Q (19%, 5/26) and R155K (11.5%, 3/26) substitutions were detected less frequently than D168V among GT-1b-infected patients. In 2 of 26 GT-1b-infected patients, no RAVs at R155 or D168 were detected. The single GT-1a-infected prior null responder relapsed with virus encoding NS3 D168V RAVs.
DISCUSSION
P REVIOUS CLINICAL STUDIES of faldaprevir plus
PegIFN/RBV have used PegIFNα-2a. In this study, we assessed the safety and efficacy of faldaprevir at 120 or 240 mg q.d., for 12 or 24 weeks, plus PegIFNα-2b/RBV, for 24 or 48 weeks, in treatment-naïve and treatmentexperienced Japanese patients with chronic GT-1 HCV infection.
Almost all patients experienced at least one drug-related AE. The most common AEs were consistent with previous studies of faldaprevir and with the use of a PegIFNα-2b/ RBV background, with the exception of pyrexia which was observed more frequently in this study than in previous studies. [7] [8] [9] [10] [11] [12] 14 Low hemoglobin was reported in 30-36% of patients, but no faldaprevir dose-response was observed. Most anemia events were managed with RBV dose reduction. Rash was reported in 45-65% of patients; most incidences were DAIDS grade 1 and the vast majority were DAIDS grade 1 or 2. The frequency of any DAIDS grade 3-4 AEs was observed to be higher with the 240 mg dose of faldaprevir than with the 120 mg dose, although DAIDS grade 4 AEs were rare across all groups. A higher incidence of some AEs with faldaprevir dosed at 240 mg compared with 120 mg was also observed in the STARTVerso1 trial. 10 Among treatment-naïve patients, there were more AE-related discontinuations of all study medications in the faldaprevir 240 mg group than in the 120 mg group (21% vs. 0%). Discontinuations of faldaprevir only due to AEs were also higher in the faldaprevir 240 mg group compared with the 120 mg group (30% vs. 2%). Notably only three (7%) treatmentexperienced patients discontinued faldaprevir 240 mg for AEs. This could reflect possible differences between the treatment populations (better tolerance of treatment among treatment-experience patients given their greater need for a cure) or may be an artifact of the small sample size, which limits these kinds of comparison.
In treatment-naïve patients, faldaprevir plus PegIFNα-2b/RBV resulted in SVR12 rates of 86% (faldaprevir 120 mg RGT) and 74% (faldaprevir 240 mg 12 weeks). These rates are similar to those achieved with faldaprevir plus PegIFNα-2a/RBV in the STARTVerso1 trial (79-80%) carried out in Europe and Japan. 10 The present study is perhaps more relevant to the Japanese HCV-infected population as the treatment-naïve patient group included only HCV GT-1b-infected individuals (the study population of STARTVerso1 represented a 34/66% mixture of GT-1a and GT-1b) and, in Japan, PegIFNα-2b/RBV is more widely used than PegIFNα-2a/RBV. Overall, more than 95% of treatment-naïve patients achieved ETS, of whom over 84% went on to achieve SVR12. Although ETS rates were similar in the faldaprevir 120 mg and 240 mg groups (98% and 93%, respectively), SVR12 rates were numerically higher among patients receiving faldaprevir 120 mg (86% vs 74%) owing to greater rate of premature discontinuation for AEs in the 240 mg group.
Among treatment-experienced patients, faldaprevir 240 mg for 24 weeks plus PegIFNα-2b/RBV resulted in SVR12 in 86% of prior relapsers. Most (>96%) prior relapsers achieved ETS and required only 24 weeks total treatment. The SVR12 rates were lower among prior partial responders or patients with breakthrough (60%) and prior null responders (40%); consistent with their previous lack of response to PegIFNα-2b/RBV, a high proportion (80%) of these patients had an IL28B non-CC genotype. It should be noted that these treatment groups had very small patient numbers. Nevertheless, SVR12 rates achieved in treatment-experienced patients in this study are comparable with those achieved with faldaprevir plus PegIFNα-2a/RBV in the STARTVerso3 trial carried out in Europe, North America, and Japan. 12 Thus, our results suggest that faldaprevir plus PegIFNα-2b/RBV is effective for patients with chronic HCV who have failed prior treatment with PegIFN/RBV, especially prior relapsers.
The SVR12 rates were lower in subgroups of patients with characteristics traditionally associated with reduced response to PegIFN-based treatments (IL28B genotype CT and baseline viral load ≥800 000 IU/mL) than in their complementary subgroups.
Some baseline HCV polymorphisms are associated with reduced response to HCV antiviral therapies. NS3 Q80K is associated with reduced response in GT-1a-infected patients treated with the NS3/4A A protease inhibitor simeprevir plus PegIFN/RBV. 15 Of note, this polymorphism is rare in GT-1b isolates and was only detected in two patients in this study. Hepatitis C virus polymorphisms at codon 70 in the core region are frequent in GT-1b isolates and may predict response to PegIFN/RBV therapy; some HCV treatment studies in Japan have shown that the amino acid arginine (R) at codon 70 in the core protein may be associated with improved SVR12. 16, 17 In the present study, no baseline NS3 protease or core polymorphism was associated with greatly reduced SVR12. This is consistent with results of comprehensive analyses of pooled data from multiple clinical studies indicating that faldaprevir RAVs are rare at baseline and that no single NS3/4A A polymorphism is associated with reduced SVR. 18, 19 The most common faldaprevir treatmentemergent RAVs in patients who did not achieve SVR12 included NS3 R155 and/or D168 amino acid substitutions; the predominant RAV in GT-1b (D168V) is consistent with previous reports. 19, 20 Limitations of this study are the lack of a control arm, differences between patients in the different treatment groups, and the small numbers of patients, particularly in the subgroups of Cohort 2 (treatment-experienced patients). Confirmation of these results would require further evaluation in larger patient groups; however, several IFNfree regimens have now been shown to offer substantial efficacy in treatment-experienced patients, [21] [22] [23] many of which are already available in some countries. The decision to re-treat prior relapsers or non-responders with an IFN-based versus an IFN-free regimen should be made for each individual patient based on factors determining the urgency to treat relative to the availability of regimens in different regions.
In conclusion, in treatment-naïve Japanese patients with chronic HCV GT-1b infection, faldaprevir at a dose of 120 mg q.d. plus PegIFNα-2b/RBV was better tolerated than faldaprevir 240 mg q.d. plus PegIFNα-2b/RBV, with at least comparable efficacy. In treatment-experienced patients, faldaprevir 240 mg q.d. plus PegIFNα-2b/RBV resulted in a high SVR12 rate among prior relapsers, with few patients discontinuing treatment.
